CASI Pharmaceuticals

CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing CANCER and other unmet medical needs for the global market, with a focus on China and the U.S.
Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Size (employees)
20 (est)
CASI Pharmaceuticals is headquartered in Rockville, US

Key People at CASI Pharmaceuticals

Ken Ren

Ken Ren

Chief Executive Officer
Sara Capitelli

Sara Capitelli

Vice President, Finance and Principal Accounting Officer

CASI Pharmaceuticals Office Locations

CASI Pharmaceuticals has offices in Rockville and Beijing
Rockville, US (HQ)
300 9620 Medical Center Dr
Beijing, CN
CASI (Beijing) Pharmaceuticals, Inc. FullLink Plaza Suite B1214, B1215 18 Chaoyangmenwai Street, Chaoyang

CASI Pharmaceuticals Data and Metrics

CASI Pharmaceuticals Financial Metrics

CASI Pharmaceuticals's revenue was reported to be $47.7 k in FY, 2015
USD

Net income (Q1, 2017)

(1.7 m)

Market capitalization (17-Aug-2017)

58.5 m

Cash (31-Mar-2017)

25.5 m
CASI Pharmaceuticals's current market capitalization is $58.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.7 k47.7 k

Revenue growth, %

101%

Cost of goods sold

7.5 k6.3 k

Gross profit

16.3 k41.4 k

Gross profit Margin, %

69%87%

R&D expense

2.8 m4.1 m4.6 m

General and administrative expense

3.8 m3.1 m4.8 m

Operating expense total

26.2 m7.2 m9.4 m

Interest expense

26.6 k81.5 k26.1 k

Interest income

81.5 k

Net Income

(5.7 m)(26.2 m)(7.2 m)(9.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cost of goods sold

6.3 k2.7 k

R&D expense

724.5 k697 k865 k1.2 m942.3 k1 m1.4 m1 m1 m

General and administrative expense

891.9 k1.2 m924.8 k857.6 k673.9 k765.1 k1.9 m676.9 k644.2 k

Operating expense total

1.6 m1.8 m1.8 m2.1 m1.6 m1.8 m3.3 m1.7 m1.7 m

Interest expense

24.2 k24.3 k24.3 k8.8 k8.8 k5.6 k

Interest income

(129)

Net Income

(3.1 m)(24.6 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

6.3 m4.9 m1.1 m8 m15.1 m10.7 m5.1 m27.1 m

Current Assets

15.4 m11 m5.6 m27.4 m

PP&E

78.1 k261.8 k218.8 k229.6 k

Total Assets

15.5 m11.3 m5.8 m27.7 m

Accounts Payable

402.5 k754.6 k884.1 k1.1 m

Current Liabilities

565.2 k919 k1.1 m1.3 m

Total Liabilities

6.9 m

Additional Paid-in Capital

421.8 m432.6 m434.1 m470.1 m

Retained Earnings

(399.1 m)(425.3 m)(432.5 m)(441.9 m)

Total Equity

14.9 m(422.2 k)20.8 m

Shares Outstanding

28.6 m32.4 m

Financial Leverage

1 x-26.8 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

13.1 m11.8 m9.5 m8 m6.4 m13.9 m18.5 m24.1 m25.5 m

Current Assets

13.2 m12.2 m9.9 m8.3 m6.8 m14.3 m18.8 m24.5 m25.9 m

PP&E

240.4 k230.6 k246.3 k245.3 k234.7 k222.8 k168.7 k184.1 k244.6 k

Total Assets

13.5 m12.4 m10.2 m8.6 m7.1 m14.5 m19 m24.8 m26.2 m

Accounts Payable

573.5 k600.2 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m

Current Liabilities

743.4 k764.2 k2.6 m2.6 m971 k2.4 m2.6 m2.6 m2.8 m

Additional Paid-in Capital

422.6 m432.2 m433 m433.4 m433.8 m446.5 m455.1 m456.5 m470.3 m

Retained Earnings

(402.1 m)(423.7 m)(427.1 m)(429.2 m)(430.8 m)(434.3 m)(437.6 m)(439.3 m)(443.6 m)

Total Equity

12.7 m837.7 k(1.8 m)(3.4 m)(4.7 m)4.6 m10 m16 m19.2 m

Financial Leverage

1.1 x14.8 x-5.6 x-2.5 x-1.5 x3.1 x1.9 x1.5 x1.4 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(26.2 m)(7.2 m)(9.5 m)

Depreciation and Amortization

48.2 k68.4 k66.5 k

Accounts Receivable

(23.7 k)23.7 k

Accounts Payable

352.2 k129.5 k180.5 k

Cash From Operating Activities

(4 m)(5.5 m)(6 m)

Cash From Investing Activities

(466.3 k)(25.4 k)(64.8 k)

Cash From Financing Activities

28 m

Interest Paid

7.5 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(3.1 m)(24.6 m)(1.8 m)(2.1 m)(1.6 m)(1.8 m)(3.3 m)(1.7 m)(1.7 m)

Depreciation and Amortization

19.2 k32.7 k

Accounts Payable

171.1 k197.8 k994.9 k969 k801.3 k783.3 k945.8 k918.9 k1.1 m

Cash From Operating Activities

(1.9 m)(2.9 m)

Cash From Investing Activities

(181.4 k)(419.6 k)
Y, 2017

Financial Leverage

1.4 x

CASI Pharmaceuticals Market Value History

Traffic Overview of CASI Pharmaceuticals

CASI Pharmaceuticals Company Life and Culture

You may also be interested in